메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
저널정보
대한신경과학회 Journal of Clinical Neurology Journal of Clinical Neurology 제10권 제3호
발행연도
2014.1
수록면
244 - 248 (5page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background and Purpose There is some controversy regarding heterozygous mutations ofthe gene encoding parkin (PARK2) as risk factors for Parkinson’s disease (PD), and all previousstudies have been performed in non-Asian populations. Dosage mutation of PARK2, rather thana point mutation or small insertion/deletion mutation, was reported to be a risk factor for familial PD; dosage mutation of PARK2 is common in Asian populations. Methods We performed a gene-dosage analysis of PARK2 using real-time polymerase chainreaction for 189 patients with early-onset PD or familial PD, and 191 control individuals. In thecase of PD patients with heterozygous gene-dosage mutation, we performed a sequencing analysis to exclude compound heterozygous mutations. The association between heterozygous mutation of PARK2 and PD was tested. Results We identified 22 PD patients with PARK2 mutations (11.6%). Five patients (2.6%)had compound heterozygous mutations, and 13 patients (6.9%) had a heterozygous mutation. The phase could not be determined in one patient. Three small sequence variations were foundin 30 mutated alleles (10.0%). Gene-dosage mutation accounted for 90% of all of the mutationsfound. The frequency of a heterozygous PARK2 gene-dosage mutation was higher in PD patientsthan in the controls. Conclusions Heterozygous gene-dosage mutation of PARK2 is a genetic risk factor for patients with early-onset or familial PD in Koreans.

목차

등록된 정보가 없습니다.

참고문헌 (26)

참고문헌 신청

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0